跳至主要内容
临床试验/EUCTR2016-000297-38-GB
EUCTR2016-000297-38-GB进行中(未招募)1 期

ong-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)

Institut de Recherches Internationales Servier (I.R.I.S)0 个研究点目标入组 200 人开始时间: 2016年4月15日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Written informed consent obtained prior any study-specific procedure (patient or parent(s) or legal representative);
  • - Patient dosed with UCART19 who completed or discontinued early from a sponsored or from any investigator-initiated study that tested UCART19, or patients who were administered UCART19 under a special access scheme (compassionate use);
  • - Female patients of childbearing potential and male patients with partners of childbearing potential must continue to use an effective method of birth control as well as their partners.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 100
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 75
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 25

排除标准

  • No exclusion criteria for this study

研究者

发起方
Institut de Recherches Internationales Servier (I.R.I.S)

相似试验

进行中(未招募)
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864
EUCTR2016-000297-38-BEInstitut de Recherches Internationales Servier (I.R.I.S)200
进行中(未招募)
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0Level: LLTClassification code 10060390Term: Leukaemia lymphoblastic acuteSystem Organ Class: 100000004864
EUCTR2016-000297-38-FRInstitut de Recherches Internationales Servier (I.R.I.S)200
进行中(未招募)
1 期
A study to evaluate the long-term safety of patients with advanced lymphoid malignancies who have been previously administered with UCART19Advanced lymphoid malignanciesMedDRA version: 20.0 Level: LLT Classification code 10060390 Term: Leukaemia lymphoblastic acute System Organ Class: 100000004864
EUCTR2016-000297-38-ESInstitut de Recherches Internationales Servier (I.R.I.S)200
招募中
不适用
ong-term follow-up study of patients who have previouslybeen exposed to UCART19
JPRN-jRCT2013190001clinical operation department International center for therapeutic research200
进行中(未招募)
1 期
ong-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors.
CTIS2024-511684-28-00Autolus Limited111